Drug Profile
IDX 21459
Alternative Names: IDX21459Latest Information Update: 24 Sep 2014
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals
- Class Antivirals; Uracil nucleotides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 24 Sep 2014 Discontinued - Phase-I for Hepatitis C in Canada (PO)
- 24 Sep 2014 Discontinued - Phase-I for Hepatitis C in Europe (PO)
- 01 Aug 2014 Idenix terminates phase I trial in Hepatitis C in Europe and Canada (NCT02112942)